• Biodesix Announces Receipt of CLIA Registration Number

    October 31, 2008 Biodesix, Inc. (the “Company”), is pleased to announce receipt of a CLIA registration number 06D1090464 which allows the Company to commercially market VeriStrat®, the serum molecular diagnostic test described in the Journal of the National Cancer Institute 2007 99(11):838-846. The Company is making VeriStrat® available to qualified physicians in locations where the ... Read more
  • Biodesix Names Douglas E. Swan, formerly of Imclone Systems Incorporated, as Vice President, Commercial Operations

    October 1, 2008 Biodesix, Inc, announced today that Douglas E. Swan has joined the Company as Vice President, Commercial Operations, reporting directly to David Brunel, Chief Executive Officer. In this newly created position, Mr. Swan will be responsible for all commercial functions related to the marketing and sales of VeriStrat®. VeriStrat represents the company’s ... Read more